Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00165347 | Protein Tyrosine Kinases (PTK) in Multiple Myeloma | completed | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00327314 | Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma | unknown | Phase 2 | 100 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Dec 28, 2006 | clinicaltrials |
| NCT00399867 | Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma. | completed | Phase 2 | 30 | Ludwig-Maximilians - University of MunichOTHER | 0 | Dec 20, 2006 | clinicaltrials |
| NCT00358020 | Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients | completed | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Dec 4, 2006 | clinicaltrials |
| NCT00396045 | Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | University of Turin, ItalyOTHER | 1 | Nov 30, 2006 | clinicaltrials |
| NCT00048464 | T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | unknown | Phase 1 / Phase 2 | 35 | Xcyte TherapiesINDUSTRY | 1 | Nov 7, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00382694 | Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | unknown | Phase 2 | 80 | Nordic Myeloma Study GroupOTHER | 1 | Sep 29, 2006 | clinicaltrials |
| NCT00378755 | Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM | unknown | Phase 2 | 62 | Korean Multiple Myeloma Working PartyOTHER | 1 | Sep 22, 2006 | clinicaltrials |
| NCT00337506 | Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Jun 16, 2006 | clinicaltrials |
| NCT00096837 | A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 8, 2006 | clinicaltrials |
| NCT00323505 | A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma | completed | Phase 2 | — | Royal Marsden NHS Foundation TrustOTHER | 1 | May 9, 2006 | clinicaltrials |
| NCT00319865 | PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | unknown | Phase 2 | 47 | Korean Multiple Myeloma Working PartyOTHER | 1 | Apr 27, 2006 | clinicaltrials |
| NCT00311337 | VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) | unknown | Phase 2 | 61 | University of WuerzburgOTHER | 3 | Apr 5, 2006 | clinicaltrials |
| NCT00078065 | Xcellerated T CellsTM in Patients With Multiple Myeloma | completed | Phase 2 | 30 | Xcyte TherapiesINDUSTRY | 1 | Nov 11, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Mar 4, 2008source: clinicaltrials